124 related articles for article (PubMed ID: 14579593)
1. Cell-based screening of active-site specific chaperone for the treatment of Fabry disease.
Fan JQ; Ishii S
Methods Enzymol; 2003; 363():412-20. PubMed ID: 14579593
[No Abstract] [Full Text] [Related]
2. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.
Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ
Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies.
Germain DP; Fan JQ
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S111-7. PubMed ID: 20040321
[TBL] [Abstract][Full Text] [Related]
4. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors.
Fan JQ; Ishii S
FEBS J; 2007 Oct; 274(19):4962-71. PubMed ID: 17894781
[TBL] [Abstract][Full Text] [Related]
5. Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease.
Okumiya T; Ishii S; Takenaka T; Kase R; Kamei S; Sakuraba H; Suzuki Y
Biochem Biophys Res Commun; 1995 Sep; 214(3):1219-24. PubMed ID: 7575533
[TBL] [Abstract][Full Text] [Related]
6. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.
Garman SC; Garboczi DN
J Mol Biol; 2004 Mar; 337(2):319-35. PubMed ID: 15003450
[TBL] [Abstract][Full Text] [Related]
7. Purification and characterization of human alpha-galactosidase A expressed in insect cells using a baculovirus vector.
Chen Y; Jin M; Goodrich L; Smith G; Coppola G; Calhoun DH
Protein Expr Purif; 2000 Nov; 20(2):228-36. PubMed ID: 11049747
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease.
Ishii S; Kase R; Sakuraba H; Suzuki Y
Biochem Biophys Res Commun; 1993 Dec; 197(3):1585-9. PubMed ID: 7904161
[TBL] [Abstract][Full Text] [Related]
9. Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease.
Citro V; Peña-García J; den-Haan H; Pérez-Sánchez H; Del Prete R; Liguori L; Cimmaruta C; Lukas J; Cubellis MV; Andreotti G
PLoS One; 2016; 11(10):e0165463. PubMed ID: 27788225
[TBL] [Abstract][Full Text] [Related]
10. 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality.
Yam GH; Roth J; Zuber C
Biochem Biophys Res Commun; 2007 Aug; 360(2):375-80. PubMed ID: 17592721
[TBL] [Abstract][Full Text] [Related]
11. Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests.
Andreotti G; Citro V; De Crescenzo A; Orlando P; Cammisa M; Correra A; Cubellis MV
Orphanet J Rare Dis; 2011 Oct; 6():66. PubMed ID: 22004918
[TBL] [Abstract][Full Text] [Related]
12. Role of Ser-65 in the activity of alpha-galactosidase A: characterization of a point mutation (S65T) detected in a patient with Fabry disease.
Ishii S; Suzuki Y; Fan JQ
Arch Biochem Biophys; 2000 May; 377(2):228-33. PubMed ID: 10845698
[TBL] [Abstract][Full Text] [Related]
13. The carboxyl terminus of coffee bean alpha-galactosidase is critical for enzyme activity.
Maranville E; Zhu A
Arch Biochem Biophys; 2000 Jan; 373(1):225-30. PubMed ID: 10620342
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetic analysis of a Chinese patient with Fabry disease.
Lam CW; Mak YT; Lo YM; Tong SF; To KF; Lai FM
Chin Med J (Engl); 2000 Feb; 113(2):186-8. PubMed ID: 11775551
[No Abstract] [Full Text] [Related]
15. Structural basis of Fabry disease.
Garman SC; Garboczi DN
Mol Genet Metab; 2002; 77(1-2):3-11. PubMed ID: 12359124
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations.
Liguori L; Monticelli M; Allocca M; Hay Mele B; Lukas J; Cubellis MV; Andreotti G
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940970
[TBL] [Abstract][Full Text] [Related]
17. A thermodynamic assay to test pharmacological chaperones for Fabry disease.
Andreotti G; Citro V; Correra A; Cubellis MV
Biochim Biophys Acta; 2014 Mar; 1840(3):1214-24. PubMed ID: 24361605
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants.
Yu Y; Mena-Barragán T; Higaki K; Johnson JL; Drury JE; Lieberman RL; Nakasone N; Ninomiya H; Tsukimura T; Sakuraba H; Suzuki Y; Nanba E; Mellet CO; García Fernández JM; Ohno K
ACS Chem Biol; 2014 Jul; 9(7):1460-9. PubMed ID: 24783948
[TBL] [Abstract][Full Text] [Related]
19. Novel human pathological mutations. Gene symbol: GLA. Disease: Fabry disease.
Chien YH; Hwu WL
Hum Genet; 2009 Apr; 125(3):336. PubMed ID: 19309781
[No Abstract] [Full Text] [Related]
20. Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.
Blom D; Speijer D; Linthorst GE; Donker-Koopman WG; Strijland A; Aerts JM
Am J Hum Genet; 2003 Jan; 72(1):23-31. PubMed ID: 12471562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
